GSK and Vir Biotechnology said on January 13 they are seeking an expansion to the U.S. approval of their antibody-based COVID-19 treatment to include an option for the therapy to be given as a shot in the arm.
If you are not happy with the results below please do another search
50 search results for:
AstraZeneca said on January 13 that preliminary data from a trial showed that the company’s COVID-19 shot Vaxzevria generated an increase in antibodies against the Omicron and other variants when given as a third booster dose.
The highly infectious Omicron coronavirus variant causes less severe disease than the Delta strain but it remains a “dangerous virus,” particularly for those who are unvaccinated, the head of the World Health Organization (WHO) said on January 12.
The U.S. Food and Drug Administration added another warning to the regulatory agency’s fact sheet for Johnson & Johnson’s COVID-19 vaccine. In other news, as the Omicron variant rips through the United States, top health officials have noted that the variant is so contagious that if you come into contact with it, you are likely to catch it.
Radiomics is a field of research in which image analysis is used to extract large number of quantitative features from medical images, such as MR, CT, and PET scans. While there are many potential applications of radiomics across the healthcare spectrum, oncology continues to be one of the main areas of study.
The spread of COVID-19 in the Americas driven by the Omicron variant of the virus reached levels of transmission never before seen during the pandemic, with cases doubling to 6.1 million over the past week, the Pan American Health Organization (PAHO) said on January 12.
Sparked by more than two years of virtual meetings due to the COVID-19 pandemic, Pfizer is cutting the company’s sales staff as more and more physicians’ offices and healthcare facilities prefer fewer face-to-face interactions with vendors. That preference for a virtual experience is expected to remain even after the pandemic wanes.
As part of a restructuring of the company’s research and development areas, Tokyo-based Daiichi Sankyo announced the closing of the Plexxikon R&D subsidiary in South San Francisco.
South Korean biotechnology firm ABL Biotechnologies signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new therapy candidate for Parkinson’s disease.
Biogen shares fell on January 12 after the Centers for Medicare and Medicaid Services (CMS) issued its draft national coverage decision for the company’s controversial Alzheimer’s drug Aduhelm.